Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tapotoclax (AMG 176) in HR-MDS and CMML
NCT05209152Phase 1Terminated
- Sponsor
- Amgen
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Tapotoclax in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (3 arms), sponsored by Amgen. Primary endpoints: Dose Limiting Toxicity and Treatment-emergent Adverse Events. Started Nov 2022; status: terminated.
02
Drugs
Tapotoclax
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05209152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05209152.